TX-FLUENCE
4.11.2021 14:02:11 CET | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, today premiered “Fluence Unfiltered,” a conversation platform for the world’s most innovative minds in horticulture science and technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005473/en/
Hosted by Fluence CEO David Cohen and available through the company’s YouTube channel, each “Fluence Unfiltered” episode features Cohen in conversation with global horticultural leaders discussing insights, innovations and trends in cannabis and food production. “Fluence Unfiltered” brings to light crucial, actionable advice cultivators and other industry players can implement today in their own operations.
“As food production remains a pressing issue for the world’s growing population and cannabis consumption continues to gain legislative momentum around the globe, growers are seeking the most advanced, efficient cultivation strategies to better serve their communities,” Cohen said. “Fluence is committed to delivering more than lighting to our customers and partners. Throughout our history, we have made it a point to bring industry players together to help the world grow smarter, together. ‘Fluence Unfiltered’ is a natural extension of our core mission. We will offer candid advice directly from the world’s leading cultivators, show you how to jumpstart your trajectory in the cannabis industry and highlight plainly what early steps you can take to optimize your operation.”
The first episode of “Fluence Unfiltered” features Michael Ward, CEO and founder of Harbor Farmz, a Kalamazoo, Michigan-based cannabis cultivator. In the episode, Ward discusses his journey to build a state-of-the-art cannabis operation from the ground up and elevate medical and adult use cannabis production in Michigan. As a groundbreaking cultivator in the Midwest, Harbor Farmz prioritizes efficient growing strategies, takes a uniquely organic approach and has integrated advanced technologies like Fluence’s LED lighting into its facilities to achieve its cultivation goals.
To view the first and future episodes of “Fluence Unfiltered,” subscribe to Fluence’s YouTube channel here . For more information on Fluence, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science .
About Harbor Farmz
Established in 2017, Harbor Farmz has become the premier choice for handcrafted organic cannabis products in Michigan. We control our cultivation, extraction, manufacturing and packaging practices all in house so that we can maintain our Harbor Farmz quality from tissue culture to sale. Since our inception, our goal has been to create a naturally potent medicine that our customers can depend upon. We focus on using organic cultivation methods to provide the highest quality flowers which then go on to become our brilliant line of extracts, concentrates and edibles. Our belief is that the highest quality inputs equal high-quality outputs. With this in mind, we developed a workforce based around a positive work culture, teamwork and equality, allowing us to ensure our passion for the industry stays as potent as our products.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005473/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom